



**Pfizer Limited**

The Capital, 1802/1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 5, 2024

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai – 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block Bandra-Kurla Complex, Bandra (E)  
Mumbai – 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Intimation regarding change in Senior Management Personnel of the Company.**

**Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations'), we hereby inform you the following changes in the Senior Management Personnel ("SMP") of the Company:

- 1) Mr. Deepak Rakheja, Category Lead – Internal Medicine has been appointed as Strategic Partnerships, Channel Development and International Neighbouring Markets Lead effective November 7, 2024. Mr. Rakheja shall continue to be a Senior Management Personnel.
- 2) Appointment of Mr. Prashant Mahalingam as Category Lead – Internal Medicine effective November 7, 2024. Mr. Prashant Mahalingam shall be a Senior Management Personnel effective the said date.
- 3) Resignation of Mr. Debashish Roy, Director – Patient & Healthcare Experience Studio from the services of the Company with effect from November 29, 2024 to pursue opportunities outside Pfizer Limited. Mr. Debashish Roy shall accordingly cease to be a Senior Management Personnel effective the said date.

Additional details required to be disclosed pursuant to the SEBI Listing Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as Annexure A (profile of the Appointees) and Annexure B (Resignation letter).

Request you to please take the above on record.

Thanking you,

Yours truly,

For **Pfizer Limited**

**Prajeet Nair**

**Director – Corporate Services & Company Secretary**

**CIN:** L24231MH1950PLC008311

**Email ID:** [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)

**Website:** [www.pfizerltd.co.in](http://www.pfizerltd.co.in)

## Annexure A

Sr. no	Particulars	Details	
1.	Name	Mr. Prashant Mahalingam	Mr. Deepak Rakheja
2.	Reasons for change	Appointment of Mr. Prashant Mahalingam as Category Lead – Internal Medicine effective November 7, 2024. He will be a part of the Senior Management Personnel effective the said date.	Appointment of Mr. Deepak Rakheja, as Strategic Partnerships, Channel Development and International Neighbouring Markets Lead effective November 7, 2024. Mr. Rakheja shall continue to be a Senior Management Personnel.
3.	Date of Appointment and Term	November 7, 2024	November 7, 2024
4.	Affirmation as per List/Comp/14/2018-19 dated June 20, 2018	Not Applicable	Not Applicable
5.	Relationship inter-se Directors / Key Managerial Personnel / Senior Management Personnel	Mr. Prashant Mahalingam is not related to any of the Directors / Key Managerial Personnel / Senior Management Personnel.	Mr. Deepak Rakheja is not related to any of the Directors / Key Managerial Personnel / Senior Management Personnel.
6.	Number of Shares held in the Company	Nil	Nil
7.	Brief Profile	<p>Mr. Prashant Mahalingam holds a Bachelors in Technology (Chemical Engineering) from IIT Madras, Post Graduate Degree in Management from IIM Calcutta and Executive Education Innovation Consortium from Tuck School of Business, University of Dartmouth.</p> <p>Mr. Mahalingam is a versatile and transformative business leader with over 25 years of experience across General Management, Sales, Marketing, Human Resources, Supply Chain, Digital Transformation, Analytics, and E-Commerce, primarily in the FMCG and Pharmaceutical sectors.</p> <p>Mr. Mahalingam joins the Company from Dr. Reddy's Laboratories Limited (DRL), where he served as the Cluster Head for the Acute Therapies (RX) and Consumer Health business.</p> <p>Prior to his role with DRL Mr. Mahalingam served as Commercial Head for Johnson &amp; Johnson's Consumer health business in Malaysia and Singapore markets.</p> <p>Mr. Mahalingam has significant experience in leading large teams, turning around businesses to deliver market-beating and sustainable growth, and spearheading new innovation-led digital ventures.</p>	<p>Mr. Deepak Rakheja holds Master's in Business Administration Degree from HEC Paris Business School. Mr. Rakheja also holds a Master of Economics Degree from University of Delhi.</p> <p>Mr. Deepak Rakheja has during his 15 years of tenure with Pfizer, helmed roles of increased scope, responsibility &amp; complexity, including Category Lead – Internal Medicine, Commercial roles, Sales Logistics &amp; Demand Management, Business Operations, Field Force Effectiveness, Training, and Commercial Compliance.</p> <p>Mr. Rakheja also lead Pfizer's Global Commercial Operations (GCO) for Africa, Middle East &amp; India. Prior to this he had also served as the Commercial Director for Growth Markets (Iran, Iraq, Syria &amp; Yemen) and the Strategic Alliances Gulf Levant Markets.</p>

## **Annexure - B**

November 5, 2024

**To,  
Managing Director  
Pfizer Limited  
Mumbai.**


Dear Madam,

**Sub: Resignation as Director – Patient & Healthcare Experience Studio of Pfizer Limited**

I hereby tender my resignation as the Director – Patient & Healthcare Experience Studio of Pfizer Limited effective from close of business hours on November 29, 2024, to pursue opportunities outside Pfizer.

I would like to thank the management and my colleagues for their support extended to me during my tenure with the Company.

Yours truly,  
Warm Regards,



**Debashish Roy**